TURKISH JOURNAL OF HEMATOLOGY, cilt.27, sa.1, ss.8-14, 2010 (SCI-Expanded)
Objective: Stable mixed chimerism (MC) may result in cure for thalassemia major patients following hematopoetic stem cell transplantation (HSCT), but rejection can occur. Twenty-eight HSCTs for thalassemia major were reviewed retrospectively to evaluate the clinical course of MC with possible risk factors and predictors of outcome, with a median follow-up of 1669 days (811-3576 days).